Profile
Per Aabakken is currently a Director at Trinity Capital Ltd. He previously worked as Acting President & Chief Executive Officer at Hafslund Nycomed AS, Chief Executive Officer at Takeda A, and Director at Mole Genetics AS.
Mr. Aabakken obtained an undergraduate degree from the Norwegian School of Economics & Business Administration.
Per Aabakken active positions
| Companies | Position | Start |
|---|---|---|
Trinity Capital Ltd.
Trinity Capital Ltd. Financial ConglomeratesFinance Private equity firm | Director/Board Member | 2009-07-22 |
Former positions of Per Aabakken
| Companies | Position | End |
|---|---|---|
Hafslund Nycomed AS
Hafslund Nycomed AS Medical SpecialtiesHealth Technology R & D of medical imaging contrast med | President | 2009-02-12 |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Chief Executive Officer | - |
Mole Genetics AS
Mole Genetics AS BiotechnologyHealth Technology Manufactures and sells instruments & pre-filled reagent cartridges for genetic research | Director/Board Member | - |
Training of Per Aabakken
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Hafslund Nycomed AS
Hafslund Nycomed AS Medical SpecialtiesHealth Technology R & D of medical imaging contrast med | Health Technology |
Trinity Capital Ltd.
Trinity Capital Ltd. Financial ConglomeratesFinance Private equity firm | Finance |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Finance |
Norwegian School of Economics & Business Administration
Norwegian School of Economics & Business Administration Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mole Genetics AS
Mole Genetics AS BiotechnologyHealth Technology Manufactures and sells instruments & pre-filled reagent cartridges for genetic research | Health Technology |
- Stock Market
- Insiders
- Per Aabakken
















